Needham & Company Reiterates a 'Buy' on Aegerion Pharmaceuticals (AEGR); When More of the Same is a Good Thing – 56-Wk Follow-up Data Consistent
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Aegerion Pharmaceuticals (NASDAQ: AEGR), PT $26.
Needham analyst says, "Today, Aegerion announced a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "Today, Aegerion announced a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
